A Phase II Trial of SU5416 (NSC #696819) in Previously Treated Patients With Advanced, Metastatic and/or Locally Recurrent Soft Tissue Sarcomas
OBJECTIVES:
I. Determine the response rate, response duration, and overall survival in patients with
advanced, metastatic, or recurrent soft tissue sarcoma or gastrointestinal stromal tumor
when treated with SU5416.
II. Determine the safety of SU5416 in these patients.
OUTLINE: This is a multicenter study.
Patients receive SU5416 IV twice weekly for 4 weeks. Treatment continues every 4 weeks in
the absence of disease progression or unacceptable toxicity.
Patients are followed monthly for 3 months and then every 3 months for 1 year.
Interventional
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
George D. Demetri, MD
Study Chair
Dana-Farber Cancer Institute
United States: Food and Drug Administration
CDR0000067893
NCT00005862
October 2000
Name | Location |
---|---|
Massachusetts General Hospital Cancer Center | Boston, Massachusetts 02114 |
Dana-Farber Cancer Institute | Boston, Massachusetts 02115 |